Annual report
4528.TEDINET S100YA20
Period2025-04-01 → 2026-03-31
Filed2026-06-15
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Amended by S100YOIE (2026-07-08).
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥515.8bn | 2025-04-01 → 2026-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥486.9bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥502.7bn | 2023-04-01 → 2024-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥447.2bn | 2022-04-01 → 2023-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥361.4bn | 2021-04-01 → 2022-03-31v | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥92.2bn | 2025-04-01 → 2026-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥59.7bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥92.7bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥59.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥163.7bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥143.5bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥105.0bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥69.8bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥50.0bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥128.0bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥112.7bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥80.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥69.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥50.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.11T | at 2026-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.06T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥913.7bn | at 2024-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥882.4bn | at 2023-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥739.2bn | at 2022-03-31v | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥249.9bn | at 2026-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥275.8bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥856.6bn | at 2026-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥788.2bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥798.6bn | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥850.7bn | at 2026-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥782.5bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥793.0bn | at 2024-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥741.9bn | at 2023-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥655.9bn | at 2022-03-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥237.0bn | at 2026-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥166.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥96.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥69.1bn | at 2022-03-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥136.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥82.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥110.7bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥159.6bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥61.8bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥39.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥136.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥48.1bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥100.3bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥6.0bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥65.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥94.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥89.8bn | 2023-04-01 → 2024-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥32.5bn | 2022-04-01 → 2023-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥60.2bn | 2021-04-01 → 2022-03-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥148.49 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥106.55 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥266.61 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥230.85 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥162.19 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥148.41 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥106.41 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥266.57 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥230.79 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥162.16 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,810.44 | at 2026-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,665.61 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,688.43 | at 2024-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,519.19 | at 2023-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,343.4 | at 2022-03-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 76.9% | at 2026-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.5% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 86.8% | at 2024-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 84.1% | at 2023-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 88.7% | at 2022-03-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 8.5% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.7% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 16.1% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.5% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 4,206 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 4,287 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 3,853 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 3,761 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 3,687 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥458.9bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥451.8bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥498.8bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥441.2bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥357.0bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥103.7bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥114.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥101.4bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥112.3bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥188.0bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥150.8bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥121.1bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥106.0bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥127.5bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥79.7bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥102.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥152.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥117.2bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥94.6bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.05T | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥1.03T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥847.3bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥804.6bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥661.9bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥209.1bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥229.0bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥844.8bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥797.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥750.2bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥685.6bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥599.2bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥199.8bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥172.0bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥169.72 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥218.02 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥318.51 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥239.96 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.51 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥169.67 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥217.98 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥318.49 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥239.94 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥190.49 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥80 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥56 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,797.89 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,697.77 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,597.16 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,403.84 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,226.79 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 80.2% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.2% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.5% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.7% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 21.3% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.2% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 498,692,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 498,692,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 498,692,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 517,425,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 528,341,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,396 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 3,464 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 3,437 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 3,381 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 3,354 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | employees | at 2026-03-31 | 4206 pure |
| Pharmaceutical Productsreportable segment | employees | at 2026-03-31 | 3396 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,929
| Item | Context | Value | Unit |
|---|---|---|---|
| Treasury shares IFRS | Prior1YearInstant | -63063000000 | JPY |
| Treasury shares IFRS | CurrentYearInstant | -62770000000 | JPY |
| Other components of equity IFRS | Prior1YearInstant | 19789000000 | JPY |
| Other components of equity IFRS | CurrentYearInstant | 48674000000 | JPY |
| Retained earnings IFRS | Prior1YearInstant | 790908000000 | JPY |
| Retained earnings IFRS | CurrentYearInstant | 830086000000 | JPY |
| Equity attributable to owners of parent IFRS | Prior1YearInstant | 782451000000 | JPY |
| Equity attributable to owners of parent IFRS | CurrentYearInstant | 850727000000 | JPY |
| Non controlling interests IFRS | Prior1YearInstant | 5751000000 | JPY |
| Non controlling interests IFRS | CurrentYearInstant | 5917000000 | JPY |
| Equity IFRS | Prior1YearInstant | 788203000000 | JPY |
| Equity IFRS | CurrentYearInstant | 856643000000 | JPY |
| Liabilities and equity IFRS | Prior1YearInstant | 1064046000000 | JPY |
| Liabilities and equity IFRS | CurrentYearInstant | 1106515000000 | JPY |
| Revenue IFRS | Prior1YearDuration | 486871000000 | JPY |
| Revenue IFRS | CurrentYearDuration | 515785000000 | JPY |
| Cost of sales IFRS | Prior1YearDuration | 147950000000 | JPY |
| Cost of sales IFRS | CurrentYearDuration | 141716000000 | JPY |
| Gross profit IFRS | Prior1YearDuration | 338921000000 | JPY |
| Gross profit IFRS | CurrentYearDuration | 374069000000 | JPY |
| Selling general and administrative expenses IFRS | Prior1YearDuration | 125671000000 | JPY |
| Selling general and administrative expenses IFRS | CurrentYearDuration | 123691000000 | JPY |
| Research and development expenditure recognized as expense during period IFRS | Prior1YearDuration | 149866000000 | JPY |
| Research and development expenditure recognized as expense during period IFRS | CurrentYearDuration | 147043000000 | JPY |
| Other income IFRS | Prior1YearDuration | 1110000000 | JPY |
| Other income IFRS | CurrentYearDuration | 913000000 | JPY |
| Other expenses IFRS | Prior1YearDuration | 4746000000 | JPY |
| Other expenses IFRS | CurrentYearDuration | 12012000000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration | 59747000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration | 92236000000 | JPY |
| Finance income IFRS | Prior1YearDuration | 4774000000 | JPY |
| Finance income IFRS | CurrentYearDuration | 3956000000 | JPY |
| Finance costs IFRS | Prior1YearDuration | 5318000000 | JPY |
| Finance costs IFRS | CurrentYearDuration | 3539000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YearDuration | 125000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYearDuration | － | JPY |
| Profit loss before tax IFRS | Prior1YearDuration | 59328000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 92654000000 | JPY |
| Income tax expense IFRS | Prior1YearDuration | 9163000000 | JPY |
| Income tax expense IFRS | CurrentYearDuration | 22743000000 | JPY |
| Profit loss IFRS | Prior1YearDuration | 50166000000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 69911000000 | JPY |
| Profit loss attributable to owners of parent IFRS | Prior1YearDuration | 50047000000 | JPY |
| Profit loss attributable to owners of parent IFRS | CurrentYearDuration | 69767000000 | JPY |
| Profit loss attributable to non controlling interests IFRS | Prior1YearDuration | 119000000 | JPY |
| Profit loss attributable to non controlling interests IFRS | CurrentYearDuration | 144000000 | JPY |
| Profit loss IFRS | Prior1YearDuration | 50166000000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 69911000000 | JPY |
| Basic earnings loss per share IFRS | Prior1YearDuration | 106.55 | |
| Basic earnings loss per share IFRS | CurrentYearDuration | 148.49 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |